[1] 杨蕊旭, 范建高. 非酒精性脂肪性肝病的流行特征 [J]. 传染病信息, 2018, 31(2): 101-104+111.
[2] Fan J G, Kim S U, Wong V W. New trends on obesity and NAFLD in Asia [J]. J Hepatol, 2017, 67(4): 862-873.
[3] Imai J, Kitamoto S, Kamada N. The pathogenic oral-gut-liver axis: new understandings and clinical implications [J]. Expert Rev Clin Immunol, 2021, 17(7): 727-736.
[4] Weintraub J A, Lopez Mitnik G, Dye B A. Oral Diseases associated with nonalcoholic fatty liver disease in the United States [J]. J Dent Res, 2019, 98(11): 1219-1226.
[5] Albuquerque-Souza E, Sahingur S E. Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis [J]. Periodontol, 2000, 2022, 89(1): 125-141.
[6] Saraval U, De Biasio B. Blood protein picture & hepatic function in periodontal diseases [J]. Minerva Med, 1957, 48(84): 3457-3463.
[7] Acharya C, Sahingur S E, Bajaj J S. Microbiota, cirrhosis, and the emerging oral-gut-liver axis [J]. JCI Insight, 2017, 2(19):e94416.
[8] Iwasaki T, Hirose A, Azuma T, et al. Correlation between ultrasound-diagnosed non-alcoholic fatty liver and periodontal condition in a cross-sectional study in Japan [J]. Sci Rep, 2018, 8(1): 7496.
[9] Alakhali M S, Al-Maweri S A, Al-Shamiri H M, et al. The potential association between periodontitis and non-alcoholic fatty liver disease: a systematic review [J]. Clin Oral Investig, 2018, 22(9): 2965-2974.
[10] Komazaki R, Katagiri S, Takahashi H, et al. Periodontal pathogenic bacteria, Aggregatibacter actinomycetemcomitans affect non-alcoholic fatty liver disease by altering gut microbiota and glucose metabolism [J]. Sci Rep, 2017, 7(1): 13950.
[11] Kuroe K, Furuta M, Takeuchi K, et al. Association between periodontitis and fibrotic progression of non-alcoholic fatty liver among Japanese adults [J]. J Clin Periodontol, 2021, 48(3): 368-377.
[12] Fujita M, Kuraji R, Ito H, et al. Histological effects and pharmacokinetics of lipopolysaccharide derived from Porphyromonas gingivalis on rat maxilla and liver concerning with progression into non-alcoholic steatohepatitis [J]. J Periodontol, 2018, 89(9): 1101-1011.
[13] Liu Y, Huang W, Dai K, et al. Inflammatory response of gut, spleen, and liver in mice induced by orally administered Porphyromonas gingivalis [J]. J Oral Microbiol, 2022, 14(1): 2088936.
[14] Yu S, Ding L, Liang D, et al. Porphyromonas gingivalis inhibits M2 activation of macrophages by suppressing alpha-ketoglutarate production in mice [J]. Mol Oral Microbiol, 2018, 33(5): 388-395.
[15] Cheng W C, van Asten S D, Burns L A, et al. Periodontitis-associated pathogens P. gingivalis and A. actinomycetemcomitans activate human CD14(+) monocytes leading to enhanced Th17/IL-17 responses [J]. Eur J Immunol, 2016, 46(9): 2211-2221.
[16] Atarashi K, Suda W, Luo C, et al. Ectopic colonization of oral bacteria in the intestine drives T(H)1 cell induction and inflammation [J]. Science, 2017, 358(6361): 359-365.
[17] Huby T, Gautier E L. Immune cell-mediated features of non-alcoholic steatohepatitis [J]. Nat Rev Immunol, 2022, 22(7): 429-443.
[18] Zheng S, Yu S, Fan X, et al. Porphyromonas gingivalis survival skills: Immune evasion [J]. J Periodontal Res, 2021, 56(6): 1007-1018.
[19] Simas A M, Kramer C D, Genco C A. Diet-induced non-alcoholic fatty liver disease and associated gut dysbiosis are exacerbated by oral infection [J]. Front Oral Health, 2021, 2: 784448.
[20] Tsuzuno T, Takahashi N, Yamada-Hara M, et al. Ingestion of Porphyromonas gingivalis exacerbates colitis via intestinal epithelial barrier disruption in mice [J]. J Periodontal Res, 2021, 56(2): 275-288.
[21] Suvan J E, Finer N, D'Aiuto F. Periodontal complications with obesity [J]. Periodontol, 2000, 2018, 78(1): 98-128.
[22] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis [J]. Nature, 2014, 513(7516): 59-64.
[23] Ding L Y, Liang L Z, Zhao Y X, et al. Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF-κB and JNK signaling pathways [J]. Oral Dis, 2019, 25(7): 1789-1797.
[24] Zaitsu Y, Iwatake M, Sato K, et al. Lipid droplets affect elimination of Porphyromonas gingivalis in HepG2 cells by altering the autophagy-lysosome system [J]. Microbes Infect, 2016, 18(9): 565-571.
[25] Scorletti E, Carr R M. A new perspective on NAFLD: focusing on lipid droplets [J]. J Hepatol, 2022, 76(4): 934-945.
[26] Ishikawa M, Yoshida K, Okamura H, et al. Oral Porphyromonas gingivalis translocates to the liver and regulates hepatic glycogen synthesis through the Akt/GSK-3beta signaling pathway [J]. Biochim Biophys Acta, 2013, 1832(12): 2035-2043.
[27] Takamura H, Yoshida K, Okamura H, et al. Porphyromonas gingivalis attenuates the insulin-induced phosphorylation and translocation of forkhead box protein O1 in human hepatocytes [J]. Arch Oral Biol, 2016, 69: 19-24.
[28] Nagasaki A, Sakamoto S, Chea C, et al. Odontogenic infection by Porphyromonas gingivalis exacerbates fibrosis in NASH via hepatic stellate cell activation [J]. Sci Rep, 2020, 10(1): 4134.
[29] Bai L, Wang Y L, Chen Y L, et al. The combination of experimental periodontitis and oral microbiota from periodontitis patients aggravates liver fibrosis in mice [J]. J Clin Periodontol, 2022, 49(10):1067-1078.
[30] Kamata Y, Kessoku T, Shimizu T, et al. Periodontal treatment and usual care for non-alcoholic fatty liver disease: a multicenter, randomized controlled trial [J]. Clin Transl Gastroenterol, 2022, 13(11):e00520.
[31] Kim J Y, Park Y M, Lee G N, et al. Association between toothbrushing and non-alcoholic fatty liver disease [J]. PLoS One, 2021, 16(5): e0243686.
[32] Nagasaki A, Sakamoto S, Arai T, et al. Elimination of Porphyromonas gingivalis inhibits liver fibrosis and inflammation in NASH [J]. J Clin Periodontol, 2021, 48(10): 1367-1378.
[33] Alves E H P, Carvalho A D S, Silva F R P, et al. Bromelain reduces the non-alcoholic fatty liver disease and periodontal damages caused by ligature-induced periodontitis [J]. Oral Dis, 2020, 26(8): 1793-1802.
[34] Dominy S S, Lynch C, Ermini F, et al. Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors [J]. Sci Adv, 2019, 5(1): eaau3333.
[35] Jeong S H, Nam Y, Jung H, et al. Interrupting oral infection of Porphyromonas gingivalis with anti-FimA antibody attenuates bacterial dissemination to the arthritic joint and improves experimental arthritis [J]. Exp Mol Med, 2018, 50(3): e460.
[36] Xing W, Gao W, Lv X, et al. The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials [J]. Front Nutr, 2022, 9: 1024678.
[37] Bourebaba Y, Marycz K, Mularczyk M, et al. Postbiotics as potential new therapeutic agents for metabolic disorders management [J]. Biomed Pharmacother, 2022, 153: 113138.
[38] Di Stefano M, Santonocito S, Polizzi A, et al. A reciprocal link between oral, gut microbiota during periodontitis: the potential role of probiotics in reducing dysbiosis-induced inflammation [J]. Int J Mol Sci, 2023, 24(2):1084.
[39] Homayouni Rad A, Pourjafar H, Mirzakhani E. A comprehensive review of the application of probiotics and postbiotics in oral health [J]. Front Cell Infect Microbiol, 2023, 13: 1120995.
[40] Xue L, Deng Z, Luo W, et al. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial [J]. Front Cell Infect Microbiol, 2022, 12: 759306.
[41] Jian J, Nie M T, Xiang B, et al. Rifaximin ameliorates non-alcoholic steatohepatitis in mice through regulating gut microbiome-related bile acids [J]. Front Pharmacol, 2022, 13: 841132.
[42] Zhang D Y, Zhu L, Liu H N, et al. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease [J]. Drug Des Devel Ther, 2019, 13: 2249-2270.
[43] Sakai Y, Arie H, Ni Y, et al. Lactobacillus pentosus strain S-PT84 improves steatohepatitis by maintaining gut permeability [J]. Journal of Endocrinology, 2020, 247(2): 169-181.
[44] Kessoku T, Imajo K, Kobayashi T, et al. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial [J]. Lancet Gastroenterol Hepatol, 2020, 5(11): 996-1007. |
